Navigation Links
Biosensor illuminates compounds to aid fight against TB
Date:5/9/2012

EAST LANSING, Mich. For his work on developing new treatments for tuberculosis, a Michigan State University researcher has been named a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation.

Robert Abramovitch of MSU's Department of Microbiology and Molecular Genetics is using a synthetic biosensor that glows green in response to conditions that mimic human tuberculosis infection. He will screen for compounds that target chronic TB infection and may help shorten therapy or treat multidrug-resistant TB, which does not respond well to existing antibiotics.

Grand Challenges Explorations funds individuals worldwide to explore ideas that can break the mold in solving persistent global health and development challenges. Abramovitch's project is one of more than 100 Grand Challenges Explorations Round 8 grants announced today by the Gates Foundation.

"Grand Challenges Explorations encourages individuals worldwide to expand the pipeline of ideas where creative, unorthodox thinking is most urgently needed," said Chris Wilson, director of Global Health Discovery and Translational Sciences at the Bill & Melinda Gates Foundation. "We're excited to provide additional funding for select grantees so that they can continue to advance their ideas toward global impact."

To receive funding, Abramovitch and other Grand Challenges Explorations Round 8 winners demonstrated a bold idea in one of five critical global heath and development topic areas that included agriculture development, immunization and nutrition.

"Combating the ongoing tuberculosis epidemic represents one of the major challenges in global health," said Abramovitch, who has appointments with MSU's colleges of Veterinary Medicine and Human Medicine, and AgBioResearch. "The required multidrug, six- to nine-month treatment regimen has fueled the emergence of drug-resistant TB, and new treatments are needed to treat this dangerous disease and reduce the overall length of drug therapy."

To accomplish that, Abramovitch is focusing on an oxygen sensing system naturally occurring in bacteria that the TB bug uses to establish a chronic infection. His project uses a biosensor that glows green when the TB bacterium senses low environmental oxygen, a cue for the bug to infect its host.

By screening more than 250,000 compounds for molecules that prevent TB from "seeing" that cue essentially blinding the bug he will find compounds that hinder the disease's ability to maintain a persistent state and allow drugs to treat the disease quicker.

"Once we identify some of those compounds, we can focus on developing new treatments," he said.

Launched in 2008, Grand Challenges Explorations is a $100 million initiative funded by the Gates Foundation. More than 600 people in 45 countries have received grants. The program, open to any discipline and organization, uses an agile, accelerated grant-making process with short two-page online applications and no preliminary data required.

Initial grants of $100,000 are awarded two times a year. Successful projects have the opportunity to receive a follow-up grant of up to $1 million.


'/>"/>
Contact: Jason Cody
codyja@msu.edu
517-432-0924
Michigan State University
Source:Eurekalert  

Related biology news :

1. Photonic crystal biosensors detect protein-DNA interactions
2. Nano-tetherball biosensor precisely detects glucose
3. UTSA wins $500,000 to develop biosensor and regenerative medicine Ph.D. program
4. New biosensors reveal workings of anti-psychotic drugs in the living brain
5. UCLA researchers show how worlds smallest coffee ring may help biosensors detect disease
6. Biosensors reveal how single bacterium gets the message to split into a swimming and a stay-put cell
7. Carbon nanotubes form ultrasensitive biosensor to detect proteins
8. Carnegie Mellon researchers create fluorescent biosensor to aid in drug development
9. Directed self-assembly of vertical nanotubes for biosensors, logic, nano-biofuel cells
10. K-State chemists biosensor may improve food, water safety and cancer detection
11. New biosensor microchip could speed up drug development, Stanford researchers say
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Biosensor illuminates compounds to aid fight against TB
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... GUELPH, ON , June 27, 2016 /PRNewswire/ - BIOREM ... it has been advised by its major shareholders, Clean ... LP, United States based venture ... common shares of Biorem (on a fully diluted, as ... for the disposition of their entire equity holdings in ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... Amgen, will join the faculty of the University of North Carolina Kenan-Flagler ... of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s ...
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology: